{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.27","value":"14.08"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"}],"units":"Participants"}],"description":"Calculated to quantify the treatment cost associated with this regimen.","dispersionType":"Standard Deviation","groups":[{"description":"Experimental","id":"OG000","title":"Arm I"}],"paramType":"MEAN","populationDescription":"182 patients were enrolled on intermediate risk chemotherapy and were evaluable for this secondary endpoint","reportingStatus":"POSTED","timeFrame":"Up to 126 days after the start of chemotherapy","title":"Days Hospitalized for Patients Who Receive Chemotherapy","type":"SECONDARY","unitOfMeasure":"Days in the hospital"}